Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Valentín Ortiz-Maldonado

Valentín Ortiz-Maldonado

Hospital Clínic de Barcelona
The major benefits of producing academic CAR T-cells 1:26
The major benefits of producing academic CAR T-cells
Valentín Ortiz-Maldonado • 10 Dec 2023
The impact of salvage and bridging therapy on CAR T-cell therapy outcomes in B-ALL: an ITT analysis 3:03
The impact of salvage and bridging therapy on CAR T-cell therapy outcomes in B-ALL: an ITT analysis
Valentín Ortiz-Maldonado • 10 Dec 2023
Var-cel shows promise for the treatment of CLL and Richter’s transformation 2:58
Var-cel shows promise for the treatment of CLL and Richter’s transformation
Valentín Ortiz-Maldonado • 10 Dec 2023
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy 2:25
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy
Valentín Ortiz-Maldonado • 8 Jun 2023
Rapid CAR manufacture
Caron Jacobson et al. • 12 May 2023
Feasibility of second CART19 administration with rituximab-based lymphodepletion in R/R B-ALL 2:26
Feasibility of second CART19 administration with rituximab-based lymphodepletion in R/R B-ALL
Valentín Ortiz-Maldonado • 8 Jun 2023
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL 3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
Career development in SCT and cellular therapy for young physicians 4:32
Career development in SCT and cellular therapy for young physicians
Valentín Ortiz-Maldonado • 22 Mar 2022
Update on the CART19-BE-02 trial 2:47
Update on the CART19-BE-02 trial
Valentín Ortiz-Maldonado • 22 Mar 2022
ARI-0001 CART19 therapy for R/R B-ALL with isolated extramedullary disease 5:17
ARI-0001 CART19 therapy for R/R B-ALL with isolated extramedullary disease
Valentín Ortiz-Maldonado • 22 Mar 2022
ARI-0001 CAR-T therapy for R/R CLL and Richter’s syndrome 4:31
ARI-0001 CAR-T therapy for R/R CLL and Richter’s syndrome
Valentín Ortiz-Maldonado • 22 Mar 2022
ARI-0001 in CD19+ malignancies: next steps 1:05
ARI-0001 in CD19+ malignancies: next steps
Valentín Ortiz-Maldonado • 3 Feb 2021
ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease 3:04
ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease
Valentín Ortiz-Maldonado • 3 Feb 2021
CART19-BE-01: ARI-0001 in CD19+ malignancies 8:14
CART19-BE-01: ARI-0001 in CD19+ malignancies
Valentín Ortiz-Maldonado • 11 Oct 2020
Sinusoidal obstruction syndrome in patients with R/R B-cell ALL 3:32
Sinusoidal obstruction syndrome in patients with R/R B-cell ALL
Valentín Ortiz-Maldonado • 1 Sep 2020
Challenges associated with CAR-T cell production 1:42
Challenges associated with CAR-T cell production
Valentín Ortiz-Maldonado • 24 Aug 2020
The content of VJHemOnc is intended for healthcare professionals